Aclaris Therapeutics (ACRS) Stock Statistics & Valuation Metrics

Aclaris Therapeutics has a market cap or net worth of $255.66M. The enterprise value is $76.62M.

Aclaris Therapeutics has 108,332,214 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aclaris Therapeutics’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is -74.82%.

The current PE Ratio of Aclaris Therapeutics is ―. Aclaris Therapeutics’s PEG ratio is -0.04.

In the last 12 months, Aclaris Therapeutics had revenue of 18.72M and earned -132.06M in profits. Earnings per share was -1.71.

In the last 12 months, operating cash flow was -42.92M and capital expenditures -35.90M, giving a free cash flow of -78.82M billion.

Aclaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Aclaris Therapeutics upcoming earnings date is Mar 3, 2026, Before Open (Confirmed).

Aclaris Therapeutics as a current ratio of 3.99, with Debt / Equity ratio of 1.80%

In the past 12 months, Aclaris Therapeutics has paid 0.00 in taxes.

Aclaris Therapeutics EV to EBITDA ratio is -3.28, with an EV/FCF ratio of -8.40.

Aclaris Therapeutics has $95.91M in cash and marketable securities with $0.00 in debt, giving a net cash position of $95.91M billion.

Gross margin is 24.18%, with operating margin of -758.18%, and net profit margin of -705.48%.

The average price target for Aclaris Therapeutics is $9.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy